Bristol-Myers Squibb Company (NYSE:BMY) is one of the best stocks to buy for beginners now. On June 12, Bristol Myers Squibb ...

Bristol Myers Squibb presents data across targeted protein degradation research including CELMoD agents and BCL6 ligand-directed degrader at EHA 2025: Princeton, New Jersey Friday ...

ARV-393 demonstrated significant single-agent activity in models of nodal T-follicular helper cell lymphoma, ...

Company to showcase preclinical studies of ARV-393, an investigational oral PROTAC BCL6 degrader, as a single agent in models ...

Bcl6 regulates the lineage stability and suppressive function of Treg cells in head and neck squamous cell carcinoma Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer ...

BCL6 is a transcriptional repressor protein and a known driver of B-cell lymphomas. Data demonstrated synergistic antitumor activity, including complete regressions, in combination with standard of ...

BCL6 is a transcriptional repressor protein and a known driver of B-cell lymphomas. Data demonstrated synergistic antitumor activity, including complete regressions, in combination with standard ...

ARV-393 is an investigational PROteolysis TArgeting Chimera (PROTAC) designed to degrade the BCL6 protein, a key driver of B-cell lymphomas. ARV-393 shows strong synergistic antitumor activity ...

The company will also highlight preclinical study of ARV-393, an investigational PROTAC BCL6 degrader, in combination with standard of care therapies. The poster highlights the potential for ARV-393 ...

Company to highlight preclinical study of ARV-393, an investigational PROTAC BCL6 degrader, in combination with standard of care therapies NEW HAVEN, Conn., April 21, 2025 (GLOBE NEWSWIRE) -- Arvinas, ...